China Biotech Globalization

China biotech globalization is the harder route represented by [[BeiGene|百济神州]] in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位. The episode contrasts global self-commercialization with the more common pattern where Chinese companies license assets to multinational pharma and keep upfront payments, milestones, and royalties.

The concept is about control and capability. A company that builds global sales, trial, regulatory, and operational functions can keep more upside, but it needs stronger products, more capital, longer execution, and tolerance for international complexity.

Key Claims

• Global self-commercialization can preserve more upside than [[BiotechLicenseOutArbitrage|license-out]].
• The route is harder because it requires commercial infrastructure, not only good molecules.
• BeiGene / 百济神州 is used as the source’s positive Chinese case because it combines product strength, chosen market, capital from the last cycle, and international execution.
• The concept is compatible with China Biotech Asset Repricing, but it chooses building over selling as the value-capture route.

Connections

• BeiGene / 百济神州 - source company example.
• China Biotech Asset Repricing, Biotech License-Out Arbitrage, and Reverse NewCo Biotech Model - alternative cross-border routes.
• New Quality Productive Forces / 新质生产力 and China Supply-Side Clearing - adjacent China industry and market context.
• Investment Risk Management - caveat around treating company cases as investment signals.